JAZZ Key Statistics, Chart & Performance
The current stock price of JAZZ is 165.14 USD. In the past month the price decreased by -3.03%. In the past year, price increased by 34.04%.
JAZZ Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ is one of the better performing stocks in the market, outperforming 86.33% of all stocks.
JAZZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health.
JAZZ Financial Highlights
Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 8.16. The EPS decreased by -58.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| Debt/Equity | 1.09 |
JAZZ Forecast & Estimates
23 analysts have analysed JAZZ and the average price target is 217.63 USD. This implies a price increase of 31.79% is expected in the next year compared to the current price of 165.14.
For the next year, analysts expect an EPS growth of -61.17% and a revenue growth 4.61% for JAZZ
JAZZ Ownership
JAZZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.6 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 20.91 | 522.96B | ||
| MRK | MERCK & CO. INC. | 12.3 | 268.99B | ||
| PFE | PFIZER INC | 7.94 | 144.42B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.84B | ||
| ZTS | ZOETIS INC | 19.89 | 55.58B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.78 | 23.21B | ||
| VTRS | VIATRIS INC | 5.68 | 15.26B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.51 | 12.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.75B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.27B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.16B |
Related stock screener links
About JAZZ
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN D04 IE
CEO: Bruce C. Cozadd
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you describe the business of JAZZ PHARMACEUTICALS PLC?
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Can you provide the latest stock price for JAZZ PHARMACEUTICALS PLC?
The current stock price of JAZZ is 165.14 USD. The price increased by 1.67% in the last trading session.
What is the dividend status of JAZZ PHARMACEUTICALS PLC?
JAZZ does not pay a dividend.
How is the ChartMill rating for JAZZ PHARMACEUTICALS PLC?
JAZZ has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists JAZZ stock?
JAZZ stock is listed on the Nasdaq exchange.
How is the valuation of JAZZ PHARMACEUTICALS PLC (JAZZ) based on its PE ratio?
The PE ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 20.24. This is based on the reported non-GAAP earnings per share of 8.16 and the current share price of 165.14 USD.
Should I buy JAZZ stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on JAZZ.